These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25249360)

  • 1. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis.
    Deleré Y; Wichmann O; Klug SJ; van der Sande M; Terhardt M; Zepp F; Harder T
    Dtsch Arztebl Int; 2014 Sep; 111(35-36):584-91. PubMed ID: 25249360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
    Regan DG; Philp DJ; Hocking JS; Law MG
    Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.
    Harder T; Wichmann O; Klug SJ; van der Sande MAB; Wiese-Posselt M
    BMC Med; 2018 Jul; 16(1):110. PubMed ID: 30016957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis.
    Lukács A; Máté Z; Farkas N; Mikó A; Tenk J; Hegyi P; Németh B; Czumbel LM; Wuttapon S; Kiss I; Gyöngyi Z; Varga G; Rumbus Z; Szabó A
    BMC Public Health; 2020 May; 20(1):691. PubMed ID: 32460747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
    ; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
    Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
    Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
    Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
    Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
    Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.
    Lu B; Kumar A; Castellsagué X; Giuliano AR
    BMC Infect Dis; 2011 Jan; 11():13. PubMed ID: 21226933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
    Burger EA; Campos NG; Sy S; Regan C; Kim JJ
    Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence.
    Brown DR; Joura EA; Yen GP; Kothari S; Luxembourg A; Saah A; Walia A; Perez G; Khoury H; Badgley D; Stanley M
    Vaccine; 2021 Apr; 39(16):2224-2236. PubMed ID: 33744051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials.
    Ibrahim Khalil A; Zhang L; Muwonge R; Sauvaget C; Basu P
    BMJ Open; 2023 Oct; 13(10):e069616. PubMed ID: 37879679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
    Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
    Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S; Zafar A; Saperi S; Amrizal M
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping the HPV vaccine crisis in Japan: Quantifying the benefits and risks of HPV vaccination in quality-adjusted life-years for appropriate decision-making.
    Kitano T
    J Infect Chemother; 2020 Mar; 26(3):225-230. PubMed ID: 31607433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
    Petry KU; Bollaerts K; Bonanni P; Stanley M; Drury R; Joura E; Kjaer SK; Meijer CJLM; Riethmuller D; Soubeyrand B; Van Damme P; Bosch X
    Hum Vaccin Immunother; 2018 Jul; 14(7):1800-1806. PubMed ID: 29553886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.